Purpose

Semaglutide is a medication  approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, Semaglutide has on people who take the drug and the drug’s effect on physical function, body composition, and aging.

Category

IRB Number
20220256HU
NCT Number
NCT05786521
Sponsor
The University of Texas Health Science Center at San Antonio -



Study Contact

Principal Investigator
Tiffany Cortes



Eligibility

Eligible Ages
Older than 65
Eligible Genders
Male and Female
Accepts Healthy Volunteers
No

Inclusion Criteria

    • Have prediabetes or diabetes
    • Living independently (not in assisted living or nursing home)

Exclusion Criteria

    • Have heart disease   
    • Have liver disease
    • Smoke

Study Design

The study involves 8 study visits over the course of approximately 6 months.  

Arm Groups

(1) Lifestyle alone

(2) Lifestyle and Semaglutide